Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Life after acquisition? Heptares CEO on living with Sosei

This article was originally published in Scrip

Executive Summary

Heptares, a structure-based drug design specialist, was one of the shinier jewels in the UK biotech crown prior to its $400m acquisition by Sosei earlier this year. CEO and chairman Malcolm Weir, who hung on to his position and even added executive vice president and chief R&D officer at Sosei to his job title, spoke to Scrip about how life has changed after being swallowed up by a Japanese pharma company, and highlights from a recent R&D day in Japan.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts